February 1, 2021
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jenn Do
Re: Landos Biopharma, Inc.
Registration Statement on Form S-1 (as amended) (File No. 333-252083)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), we, as representatives of the several underwriters, hereby join in the request of Landos Biopharma, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on February 3, 2021, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.
The undersigned advise that they have complied and will continue to comply, and that they have been informed by the participating underwriters and dealers that they have complied with and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
[SIGNATURE PAGES FOLLOW]
|J.P. MORGAN SECURITIES LLC|
|Name: David Ke|
|Title: Executive Director|
|Name: Matthew Kim|
|Title: Joint Head of U.S. Biotech|
|SVB LEERINK LLC|
|Name: Gabriel Cavazos|
|Title: Managing Director|
As Representatives of the several Underwriters.
[Signature Page to Acceleration Request (Underwriters)]